CytomX Therapeutics, Inc. - Common Stock (CTMX)

Which stocks have an unusual volume on Monday?

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

CTMX stock results show that CytomX Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Investors should consider these three penny stocks to buy before their success makes them more expensive to gain from.

It's time to take CytomX Therapeutics stock seriously as CytomX Therapeutics forges a crucial partnership with a pharmaceutical powerhouse.

Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially in pancreatic cancer, with stable disease maintained.

SoundHound AI stock is slipping on Thursday as SOUN investors appear unimpressed by a new LLM collaboration with Perplexity.

Nvidia stock fans will want to keep an eye on the tech company when June 2 rolls around for a potential catalyst for NVDA shares.

CytomX Therapeutics stock is falling hard on Thursday after the company posted lackluster results in a cancer treatment clinical trial update.

Pre-market stock movers are a hot topic this morning and we've got traders covered with all of the news behind these movements on Thursday!

CTMX stock results show that CytomX Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Pre-market stock movers are worth checking out with our coverage of all the latest and greatest news happening on Thursday!